Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | MET | P08581 | 10/20 | 0.36 |
| ▸ | CASP6 | P55212 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12878216 | 0.87 | DHFR (0.37) | DHFRNPC1METCASP6SYK | |
| SCHEMBL1163132 | 0.80 | NPC1 (0.53) | DHFRNPC1METSYKHTT | |
| SCHEMBL6522352 | 0.80 | SYK (0.38) | METSYKEGFR | |
| SCHEMBL29869683 | 0.77 | KDM4E (0.40) | NPC1KDM4EHSP90AA1HSP90AB1EGFR | |
| SCHEMBL1329723 | 0.77 | CASP6 (0.44) | DHFRMETCASP6SYKHTT | |
| SCHEMBL1163524 | 0.76 | MET (0.40) | MET | |
| SCHEMBL31037113 | 0.74 | CSF1R (0.48) | MET | |
| SCHEMBL15606358 | 0.73 | CSF1R (0.42) | — | |
| SCHEMBL16520982 | 0.72 | SYK (0.44) | DHFRMETSYK | |
| SCHEMBL1163489 | 0.72 | MET (0.41) | NPC1METCASP6HTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507676-B2 | Heterocyclic oxime compounds | NOVARTIS AG (CH) | 2013-08-13 | — | — | US | disclosed |
| US-8507676-B2 | Heterocyclic oxime compounds | NOVARTIS AG (CH) | 2013-08-13 | — | — | US | disclosed |
| US-8497368-B2 | Heterocyclic hydrazone compounds | NOVARTIS AG (CH) | 2013-07-30 | — | — | US | disclosed |
| US-8497368-B2 | Heterocyclic hydrazone compounds | NOVARTIS AG (CH) | 2013-07-30 | — | — | US | disclosed |
| US-8410264-B2 | Heterocyclic oxime compounds | NOVARTIS AG (CH) | 2013-04-02 | — | — | US | disclosed |
| US-8410264-B2 | Heterocyclic oxime compounds | NOVARTIS AG (CH) | 2013-04-02 | — | — | US | disclosed |
| US-20120302570-A1 | HETEROCYCLIC OXIME COMPOUNDS | NOVARTIS AG (CH) | 2012-11-29 | — | — | US | disclosed |
| US-20120302570-A1 | HETEROCYCLIC OXIME COMPOUNDS | NOVARTIS AG (CH) | 2012-11-29 | — | — | US | disclosed |
| US-20120142681-A1 | HETEROCYCLIC HYDRAZONE COMPOUNDS | NOVARTIS AG (CH) | 2012-06-07 | — | — | US | disclosed |
| US-20120142681-A1 | HETEROCYCLIC HYDRAZONE COMPOUNDS | NOVARTIS AG (CH) | 2012-06-07 | — | — | US | disclosed |
| EP-2018383-B1 | TRIAZOLOPYRAZINE DERIVATIVES USEFUL AS ANTI-CANCER AGENTS | PFIZER PROD INC (US) | 2011-11-09 | — | — | EP | disclosed |
| US-20110065708-A1 | HETEROCYCLIC OXIME COMPOUNDS | NOVARTIS AG (CH) | 2011-03-17 | — | — | US | disclosed |
| US-20110065708-A1 | HETEROCYCLIC OXIME COMPOUNDS | NOVARTIS AG (CH) | 2011-03-17 | — | — | US | disclosed |
| US-7732604-B2 | Triazolopyrazine derivatives | PFIZER INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-7732604-B2 | Triazolopyrazine derivatives | PFIZER INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-20100105656-A1 | TRIAZOLOPYRAZINE DERIVATIVES | PFIZER INC. | 2010-04-29 | — | — | US | disclosed |
| US-20100105656-A1 | TRIAZOLOPYRAZINE DERIVATIVES | PFIZER INC. | 2010-04-29 | — | — | US | disclosed |
| WO-2007132308-A1 | TRIAZOLOPYRAZINE DERIVATIVES USEFUL AS ANTI-CANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| US-20070265272-A1 | TRIAZOLOPYRAZINE DERIVATIVES | PFIZER INC. | 2007-11-15 | — | — | US | disclosed |
| US-20070265272-A1 | TRIAZOLOPYRAZINE DERIVATIVES | PFIZER INC. | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265272-A1 | TRIAZOLOPYRAZINE DERIVATIVES | JAK2, ABL1, CCND2 | DHFR 821/4885NPC1 2420/4885MET 2876/4885 |
| US-20120142681-A1 | HETEROCYCLIC HYDRAZONE COMPOUNDS | MET, HGF, RET | DHFR 628/4885NPC1 3359/4885MET 1/4885 |
| US-20110065708-A1 | HETEROCYCLIC OXIME COMPOUNDS | MET, ERBB2, TIE1 | DHFR 528/4885NPC1 4742/4885MET 1/4885 |
| US-20100105656-A1 | TRIAZOLOPYRAZINE DERIVATIVES | JAK2, ABL1, CCND2 | DHFR 821/4885NPC1 2420/4885MET 2876/4885 |
| US-20120302570-A1 | HETEROCYCLIC OXIME COMPOUNDS | MET, ERBB2, TIE1 | DHFR 528/4885NPC1 4742/4885MET 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.